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Dipartimento di Malattie Infettive, Parassitarie ed Immunomediate, Istituto Superiore di Sanità, Rome, Italy
The unicellular protozoan parasites of the genus Plasmodium impose on human
health worldwide the enormous burden of malaria. The possibility to genetically modify
several species of malaria parasites represented a major advance in the possibility to
elucidate their biology and is now turning laboratory lines of transgenic Plasmodium
into precious weapons to fight malaria. Amongst the various genetically modified
plasmodia, transgenic parasite lines expressing bioluminescent reporters have been
essential to unveil mechanisms of parasite gene expression and to develop in vivo
imaging approaches in mouse malaria models. Mainly the human malaria parasite
Plasmodium falciparum and the rodent parasite P. berghei have been engineered to
express bioluminescent reporters in almost all the developmental stages of the parasite
along its complex life cycle between the insect and the vertebrate hosts. Plasmodium
lines expressing conventional and improved luciferase reporters are now gaining a
central role to develop cell based assays in the much needed search of new antimalarial
drugs and to open innovative approaches for both fundamental and applied research in
malaria.
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Introduction
Half of the world population is at risk of malaria (World Health Organization, 2013), the most
common, and severe parasitic mosquito-borne disease (White et al., 2014). Five species of the
protozoan genus Plasmodium infect humans, with Plasmodium falciparum and P. vivax causing
over 200 million cases/year and P. falciparum inﬂicting virtually all the 6–700,000 annual deaths
(2013) recorded mainly in children of Sub-Saharan Africa.
The malaria parasite exhibits a complex life cycle involving an Anopheles mosquito and a
vertebrate host (Figure 1). When an infected female mosquito bites a human, the Plasmodium
sporozoites travel to the liver and invade hepatocytes, where parasites replicate as hepatic schizonts
until several thousand merozoites are produced and released in the bloodstream. In P. vivax,
but not in P. falciparum, some liver parasites remain instead quiescent (hypnozoites), resum-
ing replication, and infection after several weeks or months. Upon erythrocyte invasion in the
bloodstream Plasmodium parasites undergo asexual replication forming mature schizonts whose
rupture releases merozoites that invade new erythrocytes. Some blood stage parasites diﬀerenti-
ate instead into male and female gametocytes that, when ingested in the mosquito blood meal,
are activated to produce gametes. Gamete fusion in the insect midgut produces a zygote which
develops into a motile ookinete, traversing the gut wall, and transforming into an oocyst, where
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FIGURE 1 | Transgenic bioluminescent malaria parasites at different
stages of their development in the vertebrate and mosquito hosts. The
central diagram represents the Plasmodium life cycle, showing the progression
through the developmental stages of the parasites in the mosquito vector and in
the vertebrate host. (A) Bioluminescence imaging (BLI) of individual Plasmodium
falciparum gametocytes expressing a click beetle luciferase under a sexual
stage-specific promoter. The bright field image shows immobilized
gametocytes, highlighted in green, amongst uninfected erythrocytes; the dark
field shows the bioluminescence signal of the gametocytes incubated with
D-luciferin. Magnification bar: 15 μm. (Adapted from Cevenini et al., 2014).
(B) BLI of a mouse infected with asexual P. berghei parasites expressing a firefly
luciferase-green fluorescent protein (GFP) fusion. Heatmap of the
bioluminescent signal identifies the sites of accumulation of the parasites
(Reproduced with permission from Claser et al., 2011). (C) Fluorescence of a
firefly luciferase-GFP fusion protein expressed in P. falciparum sporozoites
contained in a oocyst and (D) obtained from the dissection of infected mosquito
salivary glands. Magnification bar: 5 μm. (E) In vivo bioluminescent signal
obtained by transgenic P. falciparum liver stage parasites developing in the
chimeric liver of a humanized mouse (C–E) are reproduced with permission
from Vaughan et al. (2012).
1000s of sporozoites are produced. The life cycle is closed when
sporozoites, migrated from the ruptured oocyst to the mosquito
salivary glands, are injected in a new human host by the insect
bite.
The pathogenesis of malaria is caused by the asexual blood
stages. In the clinical manifestations of P. falciparum malaria,
the ability of parasites to sequester in the microvasculature of
several organs, including the brain, is a major cause of disease
severity, and of a fatal outcome (Miller et al., 2002; Milner et al.,
2014; Sack et al., 2014). Consequently, the need to cure symp-
tomatic patients traditionally drove eﬀorts toward ﬁnding drugs
targeting the asexual blood stage parasites, often underestimating
the importance of eliminating also the sporozoite, and game-
tocyte transmission stages or, in P. vivax, the hypnozoites. The
recent concerning reports from South East Asia of a decreased
sensitivity of some P. falciparum infections to frontline combina-
tion therapies based on artemisinin derivatives is now calling for
renewed eﬀorts to address this emergency in the frame of a global
strategy to control malaria and eventually eradicate this deadly
parasite.
It is possible to cultivate all asexual and sexual blood stages of
P. falciparum in vitro, unlike P. vivax. Plasmodium species infect-
ing rodents have been also intensely studied as mouse models
of aspects of malaria, with P. berghei particularly exploited for
its amenability to genetic manipulation. In contrast, transgen-
esis technology has been comparatively more troublesome in
P. falciparum. This review aims to highlight the importance of
Plasmodium transgenic parasites, particularly those engineered
with bioluminescent reporters, both in the study of the funda-
mental biology of Plasmodium and in developing eﬀective anti-
malarial treatments.
Luciferase enzymes catalyze the light-producing chemical
reactions of bioluminescent organisms, in which a lumino-
genic substrate (e.g., D-luciferin) is oxidized in the presence
of ATP, yielding photons. These can be accurately measured
by a luminometer with a sensitivity and a virtual absence
of background that made bioluminescent reporters potent
and versatile tools in biology (Smale, 2010). Luciferases hold
a special place in the history of Plasmodium transgenesis:
the ﬁrst plasmid construct to be successfully transfected in
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malaria parasites contained a ﬁreﬂy (Photynus pyralis) luciferase
gene whose expression, driven by the promoter of a para-
site sexual stage-speciﬁc gene, was measured in ookinetes of
the bird parasite P. gallinaceum (Goonewardene et al., 1993).
Subsequently, luciferase reporters have been used to opti-
mize transfection techniques in Plasmodium parasites (Epp
et al., 2008; Hasenkamp et al., 2012), including the intro-
duction of the luciferase from the sea pansy Renilla reni-
formis, where use of diﬀerent substrates (D-luciferin and coelen-
terazine) enabled simultaneous detection of the two parasite
produced reporters (Militello and Wirth, 2003; Helm et al.,
2010). Since the 1990s, with the stable genetic transforma-
tion of diﬀerent species of Plasmodium (Waters et al., 1997),
luciferase reporter genes greatly contributed to elucidate key
aspects of malaria infection, from the parasite cellular biology,
protein traﬃcking, gene function, and drug resistance, in several
developmental stages throughout the Plasmodium life cycle
(Figure 1).
The Plasmodium Life Cycle Marked by
Bioluminescent Parasite
Developmental Stages
Plasmodium Mosquito Stages
Parasite sexual stage development in the mosquito vector is
crucial for the transmission of Plasmodium, and elucidating the
biology of this process may therefore lead to design novel malaria
transmission-blocking strategies. Some studies with biolumines-
cent parasites highlighted the importance of post-transcriptional
regulation acting on stability and translation of several mRNAs,
including those encoding major proteins of the gamete and
ookinete surface (Mair et al., 2006). Assays with luciferase
reporters were for instance fundamental to identify regulatory
elements in the transcripts of the P25 and P28 surface proteins
of P. gallinaceum and P. falciparum (Golightly et al., 2000;
Oguariri et al., 2006).
Plasmodium parasites expressing luciferases also improved
tool development for applied studies. A powerful bioassay to
determine parasite ability to infect mosquitoes is based on feeding
cultured Plasmodium gametocytes to mosquitoes, and it is used
to measure eﬀect of transmission blocking drugs or antibodies.
This assay is, however, technically demanding and time consum-
ing as the resulting oocysts need to be individually counted in
dissected insects. After improvements by using P. berghei para-
sites expressing a green ﬂuorescent protein (GFP) in mosquito
stages (Delves and Sinden, 2010), a transgenic line of the human
parasite P. falciparum line expressing the ﬁreﬂy luciferase in
oocysts was developed. In the resulting luminescence-based
standard membrane feeding assay (SMFA) the mean lumines-
cence intensity of individual and pooled mosquitoes accurately
quantiﬁed mean oocyst intensity, eliminating the need for
mosquito dissection, and putting the basis for signiﬁcant
SMFA scalability (Stone et al., 2014).
Toward the end of parasite development in the mosquito,
the sporozoites produced in the oocyst migrate to the insect
salivary glands. Number of salivary gland sporozoites, the only
mosquito stages infectious to a mammalian host, is an important
index of Plasmodium mosquito development. The construc-
tion of a P. berghei line where a GFP-luciferase fusion is
speciﬁcally expressed in sporozoites enabled establishment of a
simple and fast assay of sporozoite loads from whole mosquitoes
(Ramakrishnan et al., 2012).
Transmission from Mosquitoes: Sporozoites
and Liver Stages
Plasmodium sporozoites injected from an infected mosquito to a
human or rodent host start their intracellular development into
the liver hepatocytes. This clinically silent stage is the target for
prophylactic or vaccine strategies, particularly against P. vivax
long lasting hypnozoites.
Plasmodium liver stage development has been poorly explored
compared to that of blood stages partly because the in vivo and in
vitro analyses, respectively, in mouse models and in cultured liver
cells, are constrained by the necessity to sacriﬁce high numbers
of mice or by ineﬃciency of sporozoite infection of cultured
liver cells. Transgenic luciferase-expressing sporozoites improved
detection strategies introducing bioluminescence imaging (BLI)
and in vivo imaging system (IVIS) in the analysis of parasite
liver stage development in live mice and in cultured hepato-
cytes. Real-time BLI requires injection of the luciferin substrate
in the mouse or in the dissected organ and an intensiﬁed charge-
coupled photon counting video camera to measure photon emis-
sion (Franke-Fayard et al., 2006; Braks et al., 2013). BLI and IVIS
using ﬁreﬂy or sea pansy luciferases have been used for real-time,
live monitoring of the progression of rodent parasitic infection
in the whole animal or in speciﬁc organs (Ploemen et al., 2009;
Annoura et al., 2013; Manzoni et al., 2014) and to test activity of
drugs targeting liver stage infection, using P. yoelii and P. berghei
transgenic sporozoites in human liver HepG2 or Huh-7 cells and
in whole mice (Mwakingwe et al., 2009; Ramalhete et al., 2011,
2014; Derbyshire et al., 2012; Lacrue et al., 2013; Li et al., 2014;
Marcsisin et al., 2014; Zuzarte-Luis et al., 2014). To improve these
approaches, identiﬁcation of parasite promoters speciﬁcally acti-
vated in liver development was achieved in P. berghei, also in
this case relying on use of transgenic luciferase-promoter fusions
(Helm et al., 2010).
The ability to reliably quantify parasite infection in hepa-
tocytes is essential in the development of malaria vaccines.
To overcome limitations of qRT-PCR-based quantiﬁcation,
P. berghei parasites expressing a GFP-luciferase fusion were
introduced to evaluate antimalarial immunity both in vivo, in
mice where this was induced by sporozoites unable to proliferate
after irradiation or chloroquine prophylaxis, and in vitro in
Huh-7 human liver hepatoma cells (Ploemen et al., 2011; Miller
et al., 2013). Luciferase expressing P. berghei and P. falciparum
sporozoites were also used to assess adequacy of sporozoite atten-
uation, obtained this time by genetic mutation, respectively, in in
vivo murine malaria model and in primary human hepatocytes
(Annoura et al., 2012; van Schaijk et al., 2014). These studies high-
lighted the role of cell mediated immunity mounting against the
multiplication-deﬁcient sporozoites. A role for antibody medi-
ated immunity was instead shown by BLI of luciferase-expressing
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sporozoites of the human parasite P. falciparum in mice with a
humanized liver, showing that infection in this organ was reduced
by passive transfer of a monoclonal antibody targeting the sporo-
zoite surface protein CSP (Sack et al., 2014). Finally, P. berghei
and P. yoelii luciferase transgenic parasites were instrumental to
evaluate modes of sporozoite administration, a critical bottleneck
in immunization, and challenge protocols (Ploemen et al., 2013).
From the Liver to the Blood: the Asexual
Erythrocytic Stages
Maturation of the liver schizont releases 1000s of merozoites
that invade blood stream erythrocytes and starts the asexual,
symptomatic blood stage infection. In P. falciparum the blood
stage schizonts disappear from circulation as they adhere to host
ligands on endothelial cells of the microvasculature in several
organs, especially in the brain and in the placenta, through
parasite proteins expressed on the infected erythrocyte surface,
leading to severe pathogenesis such as cerebral malaria or adverse
eﬀects during pregnancy. As parasites are observed to accumulate
in several organs, including the brain, also in the mouse malaria
model, real-time BLI in whole mice or in dissected organs were
conducted with P. berghei transgenic lines expressing luciferase
under a constitutive or a schizont-speciﬁc promoter to identify
the involved components of the immune system (Franke-Fayard
et al., 2005; Amante et al., 2007; Spaccapelo et al., 2010; Claser
et al., 2011; Pasini et al., 2013; Imai et al., 2014).
The need to elucidate the mechanisms of malaria pathogenesis
directed research on the fundamental biology of parasite asex-
ual development, one important aspect being how the parasite
regulates its gene expression. The extremely high A+T content
of the Plasmodium genomes however, prevented homology based
identiﬁcation of promoters, regulatory elements, and parasite
transcription factors, whereas luciferase reporters proved to be of
paramount importance in functionally identifying gene promot-
ers and regulatory regions (Horrocks and Kilbey, 1996; Porter,
2002; Militello et al., 2004; Hasenkamp et al., 2013a). This work
identiﬁed sequences functioning as bi-directional promoters,
like the intergenic region of the P. berghei elongation factor-1α
(ef-1α) gene (de Koning-Ward et al., 1999; Fernandez-Becerra
et al., 2003) or the intron of the P. falciparum var genes (Epp
et al., 2008), or evaluated whether speciﬁc promoters from one
Plasmodium species were able (Fernandez-Becerra et al., 2003;
Ozwara et al., 2003), or unable (Azevedo and del Portillo, 2007)
to recruit the transcriptional machinery of a diﬀerent malaria
species. Importantly, luciferase expressing parasites were used to
identify regulatory regions governing the expression of the P.
falciparum polymorphic var genes encoding the parasite seques-
tration ligands, whose expression switch is responsible for para-
site antigenic variation, and immune evasion (Deitsch et al., 1999;
Calderwood et al., 2003; Frank et al., 2006; Muhle et al., 2009).
In summary, luciferase reporters not only contributed to identify
functional elements involved in parasite gene regulation (Bischoﬀ
et al., 2000; Militello et al., 2004; López-Estraño et al., 2007;
Gopalakrishnan and López-Estraño, 2010; Zhang et al., 2011;
Patakottu et al., 2012), but also were essential to select speciﬁc
promoters in the development of Plasmodium inducible expres-
sion systems (de Azevedo et al., 2012; Kolevzon et al., 2014)
and to test new regulatory regions in chromosomally integrated
luciferase cassettes (Ekland et al., 2011; Weiwer et al., 2011; Che
et al., 2012; Khan et al., 2012; Hasenkamp et al., 2013b).
A major eﬀort in the ﬁght against malaria, particularly
P. falciparum, has been the screening for new antimalarial
drugs, an endeavor that the appearance of artemisinin resis-
tance in South East Asia makes dramatically urgent. In the
past decades, in vitro methods measuring the incorporation
of [3H]-labeled hypoxanthine and ethanolamine or the activity
of parasite Lactate Dehydrogenase have been the standard for
P. falciparum cell based assays and used in large drug screen-
ings (Fidock, 2010). The demand for high-throughput, non-
radioactive assays prompted to exploit also in Plasmodium the
high sensitivity and virtual absence of background of luciferase
reporters, until recently used in this ﬁeld only to study expres-
sion of the P. falciparum multidrug resistance gene pfmdr1 in
drug treated parasites (Myrick et al., 2003; Waller et al., 2003).
To this aim a P. falciparum line expressing the ﬁreﬂy luciferase
under the heat shock protein 86 (pfhsp86) gene promoter in
asexual stages enabled establishment of a cell-based luciferase
drug screening assay in 96w plates (Cui et al., 2008), subse-
quently adapted to 384w plate using 105–106 parasites per well
(Lucumi et al., 2010). Also P. berghei parasites expressing a ﬁre-
ﬂy luciferase-GFP fusion were used for in vitro and in vivo
bioluminescence drug assay, enabling use of animal models to
test new drugs in vivo (Franke-Fayard et al., 2008; Lin et al.,
2013).
Preparing Departure from the Blood: the
Gametocytes
Plasmodium gametocytes are the parasite sexual stages responsi-
ble for the transmission from the vertebrate host to the mosquito.
Male and female gametocytes are formed in the bloodstream and,
in P. falciparum, they mature in 10 days through ﬁve devel-
opmental stages. Upon ingestion in the mosquito gut, mature
gametocytes promptly diﬀerentiate into gametes and fertilization
ensures parasite infection in the insect vector. A key priority
in the present goal to globally eliminate malaria is to iden-
tify new drugs targeting in the bloodstream both the asex-
ual and the sexual stages of the parasite. However, the non-
replicative nature of gametocytes imposed to develop speciﬁc
cell based screening assays, diﬀerent from those used for asex-
ual stages. One problem is for instance that of false nega-
tive signals due to the persistence of ﬂuorescent reporter or
of parasite enzyme activities in unhealthy or dying gameto-
cytes. P. falciparum lines expressing a GFP-ﬁreﬂy luciferase gene
under gametocyte speciﬁc promoters were established (Adjalley
et al., 2011) and used in high-throughput screening assays of
compounds with anti-asexual stage activity (Lucantoni et al.,
2013). Recently, luciferase-based gametocyte assays have been
improved by replacing the commonly used commercial luciferase
substrates with an ATP-free, non-lysing D-luciferin formulation,
yielding assay readouts that more reliably monitored viabil-
ity and sensitivity to compounds of the treated gametocytes
(Cevenini et al., 2014). In this work, absence of parasite cell
lysis and the introduction in P. falciparum of the use of a
potent luciferase from Pyrophorus plagiophthalamus under a
Frontiers in Microbiology | www.frontiersin.org 4 May 2015 | Volume 6 | Article 391
Siciliano and Alano Bioluminescent Plasmodium in malaria research
gametocyte promoter enabled to perform for the ﬁrst time BLI
at the level of single parasite cells, individually distinguishing live
and dead P. falciparum gametocytes (Cevenini et al., 2014).
Multiplexing, Subcellular Localization,
Imaging: the Future in the Use of
Bioluminescent Malaria Parasites
Virtually all stages of the complex life cycle of malaria para-
sites have been enlightened by the use in several studies of
luciferase reporters. These engineered parasites provided key
answers to fundamental biological questions and now repre-
sent important tools for drug screening. Novel potent reporters
have already expanded the luciferase repertoire used in P. falci-
parum beyond the P. pyralis and Renilla enzymes (Azevedo et al.,
2014; Cevenini et al., 2014), increasing sensitivity and enabling
to further reduce parasite numbers in high-throughput screen-
ing assays, a non-trivial improvement when using speciﬁc stages
(e.g., the gametocytes) whose cultivation is technically demand-
ing. Nevertheless exploitation of the full potential of biolumi-
nescent reporters in malaria research is just moving the ﬁrst
steps.
The possibility to tune luciferase emission properties, such
as emission wavelength, kinetics or termo- and pH-stability, via
random or site-directed mutagenesis or use of enzyme natu-
ral variants, led to introduce multicolor bioluminescence in
antimalarial drug screening. A green and a red light emitting
luciferase from P. plagiophthalamus were expressed in P. falci-
parum immature and mature gametocytes, providing for the
ﬁrst time the possibility to simultaneously measure diﬀerential,
stage speciﬁc eﬀects of drugs in a dual-color luciferase assay, and
opening the possibility to apply multicolor bioluminescence to
any parasite stage in fundamental and applied studies. A dual
expression system with distinct luciferases would for instance be
valuable in cell based high-throughput screenings to readily iden-
tify and discard compounds active against the reporter rather
than the target cell (Thorne et al., 2012), as they will most likely
aﬀect only one luciferase type.
Another promising application of luciferase reporters is
through their fusion to speciﬁc signals used by the parasite to
traﬃc proteins in diﬀerent extra cellular compartments of the
infected erythrocyte. As protein export is uniquely regulated in
the parasite and is essential for its survival, use of such fusions
may be invaluable to screen for compounds targeting this process.
Preliminary studies were conducted with the P. pyralis enzyme
(Burghaus and Lingelbach, 2001) and more recent work estab-
lished P. falciparum lines which express a brighter deep-sea
shrimp luciferase equipped with sequences driving the reporter in
the parasite cytoplasm or in erythrocyte compartments (Azevedo
et al., 2014).
In another ﬁeld of application, the achievement of single para-
site cell BLI and the availability of luciferases whose red-shifted
light emission is more eﬃciently detectable from blood and
tissues are paving the road to signiﬁcant progress in analyses of
the host-parasite interplay. Co-cultures of diﬀerent P. falciparum
stages and human cell types in vitro can provide new insights of
the physiology of asexual and sexual stage parasite sequestration.
The increased sensitivity achieved in in vivomouse imaging with
a red-shifted luciferase expressed by the unicellular protozoan
parasite Trypanosoma brucei (Van Reet et al., 2014) is promis-
ing in view of use also in Plasmodium infected mice. Importantly,
the increasing availability of humanized mouse models for
P. falciparum and P. vivax infections, supporting development of
asexual, and sexual blood stages and of liver stages (Kaushansky
et al., 2014) and the use of P. falciparum transgenic lines with a
luciferase expressed constitutively (Vaughan et al., 2012) or under
stage-speciﬁc promoters are expected to answer many unsolved
questions.
The wealth of biological information provided by the use
of engineered bioluminescent malaria parasites, not to mention
those not reviewed here expressing a variety of ﬂuorescent
reporters, has been and will most likely continue to be enormous.
The conﬁned use of these whole cell biosensors in laboratory
settings does not pose regulatory concerns on environmental
release. From their aseptic sites of utilization, these genetically
modiﬁed parasites will nevertheless have the most signiﬁcant
impact in the real world, contrasting the unbearable burden of
a worldwide devastating disease.
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